Saeki I, Shimose S, Tomonari T, Ito T, et al. Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy. PLoS One 2024;19:e0311084.
PMID: 39321197